Shire shakes off generic threat

Wednesday 1 August 2012

The financial results of Shire Plc released on 1 August 2012 indicate that the US based and Dublin headquartered company will be able to withstand genetic encroachment on its franchise for treating children with ADHD (attention deficit, hyperactivity disorder).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Ireland